Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Ovarian Neoplasms

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 66 articles: HTML format Text format

Single Articles

March 2018
1. COLOMBO N, Huang G, Scambia G, Chalas E, et al
   Evaluation of a Streamlined Oncologist-Led BRCA Mutation Testing and Counseling Model for Patients With Ovarian Cancer.
   J Clin Oncol. 2018 Mar 20:JCO2017762781. doi: 10.1200/JCO.2017.76.2781.
   PubMed     Text format     Abstract available
   
   
   October 2017
2. BERCHUCK A, Secord AA, Moss HA, Havrilesky LJ, et al
   Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
   J Clin Oncol. 2017 Oct 26:JCO2017745752. doi: 10.1200/JCO.2017.74.5752.
   PubMed     Text format    
   
   
   August 2017
3. PIGNATA S, Scambia G, Bologna A, Signoriello S, et al
   Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
   J Clin Oncol. 2017 Aug 21:JCO2017734293. doi: 10.1200/JCO.2017.73.4293.
   PubMed     Text format     Abstract available
   
   
   
4. CHILDERS CP, Childers KK, Maggard-Gibbons M, Macinko J, et al
   National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer.
   J Clin Oncol. 2017 Aug 18:JCO2017736314. doi: 10.1200/JCO.2017.73.6314.
   PubMed     Text format     Abstract available
   
   
   July 2017
5. SAMIMI G, Bernardini MQ, Brody LC, Caga-Anan CF, et al
   Traceback: A Proposed Framework to Increase Identification and Genetic Counseling of BRCA1 and BRCA2 Mutation Carriers Through Family-Based Outreach.
   J Clin Oncol. 2017;35:2329-2337.
   PubMed     Text format     Abstract available
   
   
   
6. WILLMANN JK, Bonomo L, Carla Testa A, Rinaldi P, et al
   Ultrasound Molecular Imaging With BR55 in Patients With Breast and Ovarian Lesions: First-in-Human Results.
   J Clin Oncol. 2017;35:2133-2140.
   PubMed     Text format     Abstract available
   
   
   May 2017
7. BERCHUCK A, Havrilesky LJ, Kauff ND
   Is There a Role for Ovarian Cancer Screening in High-Risk Women?
   J Clin Oncol. 2017;35:1384-1386.
   PubMed     Text format    
   
   
   April 2017
8. CHRISTIE EL, Fereday S, Doig K, Pattnaik S, et al
   Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer.
   J Clin Oncol. 2017;35:1274-1280.
   PubMed     Text format     Abstract available
   
   
   
9. KONECNY GE
   Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.
   J Clin Oncol. 2017;35:1151-1153.
   PubMed     Text format    
   
   
   
10. SHAIKH F, Cullen JW, Olson TA, Pashankar F, et al
    Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children's Oncology Group.
    J Clin Oncol. 2017;35:1203-1210.
    PubMed     Text format     Abstract available
    
    
    
11. LHEUREUX S, Bruce JP, Burnier JV, Karakasis K, et al
    Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
    J Clin Oncol. 2017;35:1240-1249.
    PubMed     Text format     Abstract available
    
    
    
12. TAYLOR JS, Rajan SS, Zhang N, Meyer LA, et al
    End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer.
    J Clin Oncol. 2017 Apr 7:JCO2016702894. doi: 10.1200/JCO.2016.70.2894.
    PubMed     Text format     Abstract available
    
    
    
13. GERSHENSON DM, Bodurka DC, Coleman RL, Lu KH, et al
    Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.
    J Clin Oncol. 2017;35:1103-1111.
    PubMed     Text format     Abstract available
    
    
    
14. MOORE KN, Martin LP, O'Malley DM, Matulonis UA, et al
    Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study.
    J Clin Oncol. 2017;35:1112-1118.
    PubMed     Text format     Abstract available
    
    
    February 2017
15. ROSENTHAL AN, Fraser LS, Philpott S, Manchanda R, et al
    Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study.
    J Clin Oncol. 2017 Feb 27:JCO2016699330. doi: 10.1200/JCO.2016.69.9330.
    PubMed     Text format     Abstract available
    
    
    January 2017
16. FOTOPOULOU C, Sehouli J, Aletti G, Harter P, et al
    Value of Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer: A European Perspective.
    J Clin Oncol. 2017 Jan 9:JCO2016710723.
    PubMed     Text format    
    
    
    December 2016
17. RUTTEN MJ, van Meurs HS, van de Vrie R, Gaarenstroom KN, et al
    Laparoscopy to Predict the Result of Primary Cytoreductive Surgery in Patients With Advanced Ovarian Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Dec 28:JCO2016692962.
    PubMed     Text format     Abstract available
    
    
    
18. COPUR MS, Gauchan D, Ramaekers R, Crockett D, et al
    Neoadjuvant Chemotherapy or Primary Debulking Surgery for Stage IIIC Ovarian Cancer.
    J Clin Oncol. 2016 Dec 28:JCO2016707125.
    PubMed     Text format    
    
    
    
19. LIU JF, Ray-Coquard I, Selle F, Poveda AM, et al
    Randomized Phase II Trial of Seribantumab in Combination With Paclitaxel in Patients With Advanced Platinum-Resistant or -Refractory Ovarian Cancer.
    J Clin Oncol. 2016;34:4345-4353.
    PubMed     Text format     Abstract available
    
    
    
20. SCHRAM AM, Iasonos A, Hyman DM
    Picking the Right Patient for Human Epidermal Growth Factor Receptor 3-Targeted Therapy in Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2016;34:4312-4314.
    PubMed     Text format    
    
    
    
21. LEIJEN S, van Geel RM, Sonke GS, de Jong D, et al
    Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months.
    J Clin Oncol. 2016;34:4354-4361.
    PubMed     Text format     Abstract available
    
    
    September 2016
22. MEYER LA, Cronin AM, Sun CC, Bixel K, et al
    Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer.
    J Clin Oncol. 2016 Sep 6. pii: JCO681239.
    PubMed     Text format     Abstract available
    
    
    August 2016
23. WRIGHT AA, Bohlke K, Armstrong DK, Bookman MA, et al
    Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.
    J Clin Oncol. 2016 Aug 8. pii: JCO686907.
    PubMed     Text format     Abstract available
    
    
    June 2016
24. WENTZENSEN N, Poole EM, Trabert B, White E, et al
    Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.
    J Clin Oncol. 2016 Jun 20. pii: JCO668178.
    PubMed     Text format     Abstract available
    
    
    
25. KURZEDER C, Bover I, Marme F, Rau J, et al
    Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).
    J Clin Oncol. 2016 Jun 6. pii: JCO660787.
    PubMed     Text format     Abstract available
    
    
    May 2016
26. ABDERRAHMAN B, Jordan VC
    Estrogen Deprivation Therapy in Ovarian Cancer: An Opportunity.
    J Clin Oncol. 2016 May 23. pii: JCO673137.
    PubMed     Text format    
    
    
    March 2016
27. KILICKAP S, Tural D
    Does Adjuvant Hormone Therapy Improve Survival in Epithelial Ovarian Cancer?
    J Clin Oncol. 2016 Mar 21. pii: JCO653683.
    PubMed     Text format    
    
    
    
28. VOUTSADAKIS IA
    On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer.
    J Clin Oncol. 2016 Mar 21. pii: JCO663245.
    PubMed     Text format    
    
    
    
29. VERGOTE I, Armstrong D, Scambia G, Teneriello M, et al
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Assess Efficacy and Safety of Weekly Farletuzumab in Combination With Carboplatin and Taxane in Patients With Ovarian Cancer in First Platinum-Sensitive Relapse.
    J Clin Oncol. 2016 Mar 21. pii: JCO632596.
    PubMed     Text format     Abstract available
    
    
    
30. WRIGHT AA, Cronin A, O'Malley DM
    Reply to G.B. Holt.
    J Clin Oncol. 2016;34:1016-7.
    PubMed     Text format    
    
    
    
31. TUNG N, Lin NU, Kidd J, Allen BA, et al
    Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO650747.
    PubMed     Text format     Abstract available
    
    
    
32. CHAN JK, Monk BJ
    Reply to F.M. Muggia.
    J Clin Oncol. 2016;34:882-3.
    PubMed     Text format    
    
    
    
33. BOOKMAN MA, Brady MF
    Reply to F.M. Muggia.
    J Clin Oncol. 2016;34:884.
    PubMed     Text format    
    
    
    
34. SCHRADER KA, Stratton KL, Murali R, Laitman Y, et al
    Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant.
    J Clin Oncol. 2016;34:e61-7.
    PubMed     Text format    
    
    
    February 2016
35. LOPES LF, Macedo CR, Aguiar Sdos S, Barreto JH, et al
    Lowered Cisplatin Dose and No Bleomycin in the Treatment of Pediatric Germ Cell Tumors: Results of the GCT-99 Protocol From the Brazilian Germ Cell Pediatric Oncology Cooperative Group.
    J Clin Oncol. 2016;34:603-10.
    PubMed     Text format     Abstract available
    
    
    
36. LAMM W, Schiefer A, Nobauer IM, Horvat R, et al
    Aromatase Inhibitor Therapy As Effective Rescue in a Patient With Tamoxifen-Refractory Metastatic Granulosa Cell Tumor of the Ovary.
    J Clin Oncol. 2016;34:e31-3.
    PubMed     Text format    
    
    
    
37. MUGGIA FM
    Intraperitoneal Therapy for Ovarian Cancer.
    J Clin Oncol. 2016 Feb 1. pii: JCO628370.
    PubMed     Text format    
    
    
    January 2016
38. BOULAY RM
    Beautiful Imperfections.
    J Clin Oncol. 2016;34:286-7.
    PubMed     Text format    
    
    
    
39. HORN C, Campbell G, Hagan T, Bovbjerg DH, et al
    Associations between peripheral neuropathy and nausea/vomiting in survivors of ovarian cancer: Evidence of persistent vagal neuropathies?
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available
    
    
    
40. ANGARITA A, Cristello A, Lippitt M, Nickles Fader A, et al
    The "little big things": A qualitative study of ovarian cancer survivors and their experiences with the health care system.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available
    
    
    
41. GASPARRI ML, Crispino S, La Russa C, Marchetti C, et al
    A 10-year age-related survival analysis on cytoreductive surgery in stage IIIC-IV ovarian cancer: Elderly versus younger women.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available
    
    
    
42. BLACKMON JE, Recklitis CJ, Wright AA
    Preliminary results from the Sexual Therapy and Rehabilitation after Treatment for Ovarian Cancer (START-OC) study.
    J Clin Oncol. 2016;34.
    PubMed     Text format     Abstract available
    
    
    
43. HOLT GB
    Potential Simpson's Paradox in Multicenter Study of Intraperitoneal Chemotherapy for Ovarian Cancer.
    J Clin Oncol. 2016 Jan 11. pii: JCO644542.
    PubMed     Text format    
    
    
    
44. PUJADE-LAURAINE E, Selle F, Weber B, Ray-Coquard IL, et al
    Volasertib Versus Chemotherapy in Platinum-Resistant or -Refractory Ovarian Cancer: A Randomized Phase II Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire Study.
    J Clin Oncol. 2016 Jan 11. pii: JCO621474.
    PubMed     Text format     Abstract available
    
    
    
45. MENON U, Kalsi JK, Gentry-Maharaj A, Ryan A, et al
    Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al.
    J Clin Oncol. 2016;34:201-2.
    PubMed     Text format    
    
    
    
46. PINSKY PF
    Definition of Specificity in a Screening Trial.
    J Clin Oncol. 2016;34:198.
    PubMed     Text format    
    
    
    November 2015
47. CRUM CP
    Preventing Ovarian Cancer.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.62.9519.
    PubMed     Text format    
    
    
    
48. MCINTOSH MW, Drescher C, Fitzgibbon MM
    Ovarian Cancer Early Detection Needs Better Imaging, Not Better Algorithms or Biomarkers.
    J Clin Oncol. 2015 Nov 16. pii: JCO.2015.63.7843.
    PubMed     Text format    
    
    
    October 2015
49. HOMICSKO K, Coukos G
    Targeting Programmed Cell Death 1 in Ovarian Cancer.
    J Clin Oncol. 2015 Oct 26. pii: JCO.2015.63.7785.
    PubMed     Text format    
    
    
    
50. ALETTI GD, Bristow RE, Chi D, Cliby WA, et al
    There Is Nothing New Under the Sun.
    J Clin Oncol. 2015;33:3520.
    PubMed     Text format    
    
    
    
51. HOROWITZ N, Miller A, Rungruang B, Richard S, et al
    Reply to G.D. Aletti et al.
    J Clin Oncol. 2015;33:3521-2.
    PubMed     Text format    
    
    
    
52. LIPKOWITZ S, Kohn EC
    To Treat or Not to Treat: The Use of Hormone Replacement Therapy in Patients With Ovarian Cancer.
    J Clin Oncol. 2015 Oct 5. pii: JCO.2015.63.6670.
    PubMed     Text format    
    
    
    September 2015
53. EELES RA, Morden JP, Gore M, Mansi J, et al
    Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial.
    J Clin Oncol. 2015 Sep 28. pii: JCO.2015.60.9719.
    PubMed     Text format     Abstract available
    
    
    
54. HAMANISHI J, Mandai M, Ikeda T, Minami M, et al
    Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
    J Clin Oncol. 2015 Sep 8. pii: JCO.2015.62.3397.
    PubMed     Text format     Abstract available
    
    
    August 2015
55. GRISHAM RN, Sylvester BE, Won H, McDermott G, et al
    Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer.
    J Clin Oncol. 2015 Aug 31. pii: JCO.2015.62.4726.
    PubMed     Text format     Abstract available
    
    
    
56. GERSHENSON DM, Bodurka DC, Lu KH, Nathan LC, et al
    Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor.
    J Clin Oncol. 2015;33:2675-82.
    PubMed     Text format     Abstract available
    
    
    
57. PENDLEBURY A, Rischin D, Ireland-Jenkin K, Toner GC, et al
    Ovarian Growing Teratoma Syndrome With Spuriously Elevated alpha-Fetoprotein.
    J Clin Oncol. 2015;33:e99-100.
    PubMed     Text format    
    
    
    
58. POVEDA AM, Selle F, Hilpert F, Reuss A, et al
    Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
    J Clin Oncol. 2015 Aug 17. pii: JCO.2015.63.1408.
    PubMed     Text format    
    
    
    
59. SONG H, Dicks E, Ramus SJ, Tyrer JP, et al
    Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.
    J Clin Oncol. 2015 Aug 10. pii: JCO.2015.61.2408.
    PubMed     Text format     Abstract available
    
    
    
60. WRIGHT AA, Cronin A, Milne DE, Bookman MA, et al
    Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer.
    J Clin Oncol. 2015 Aug 3. pii: JCO.2015.61.4776.
    PubMed     Text format     Abstract available
    
    
    
61. BOHM S, Faruqi A, Said I, Lockley M, et al
    Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    J Clin Oncol. 2015;33:2457-63.
    PubMed     Text format     Abstract available
    
    
    June 2015
62. HE W, Fang F, Varnum C, Eriksson M, et al
    Predictors of Discontinuation of Adjuvant Hormone Therapy in Patients With Breast Cancer.
    J Clin Oncol. 2015 Jun 1. pii: JCO.2014.59.3673.
    PubMed     Text format     Abstract available
    
    
    May 2015
63. MENON U, Ryan A, Kalsi J, Gentry-Maharaj A, et al
    Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening.
    J Clin Oncol. 2015 May 11. pii: JCO.2014.59.4945.
    PubMed     Text format     Abstract available
    
    
    
64. MOURITS MJ, de Bock GH, Hollema H
    Pathologic findings at risk-reducing surgery.
    J Clin Oncol. 2015;33:1514.
    PubMed     Text format    
    
    
    
65. HERZOG TJ, Coleman RL, Monk BJ, Armstrong DK, et al
    In assessing surrogate clinical trial end points: drug safety is a requisite.
    J Clin Oncol. 2015;33:1511-2.
    PubMed     Text format    
    
    
    April 2015
66. SCOTT CL, Swisher EM, Kaufmann SH
    Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
    J Clin Oncol. 2015;33:1397-406.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Ovarian Neoplasms is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: